ecrin-mdr-crcClinical2022IPD Sharing (as of October 2023): Yes Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu URL: https://www.janssen.com/clinical-trials/transparencyAdvanced or Metastatic Colorectal CancerColorectal NeoplasmsAdvanced Or Metastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2730981Puerto RicoUnited StatesUnited KingdomMalaysiaSpainCanadaSouth KoreaBelgiumChinaTaiwanItalyAustraliaFranceGermany7IrinotecanAmivantamab-vmjwOxaliplatinLeucovorinAmivantamabFluorouracilECRIN MDRRecruitingfalseA Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerThe purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts).2022-07-152730981NCT053795952021-006629-23